TheraVet SA (ALVET.PA)
EUR 0.11
(-0.46%)
EUR 0.11
(-0.46%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.57 Million EUR | 33.54% |
| 2022 | -2.36 Million EUR | -76.25% |
| 2021 | -1.34 Million EUR | -245.17% |
| 2020 | -388.46 Thousand EUR | -292.65% |
| 2019 | -98.93 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -424.35 Thousand EUR | 0.0% |
| 2024 Q1 | -424.35 Thousand EUR | -27.52% |
| 2023 Q2 | -905.15 Thousand EUR | -100.0% |
| 2023 Q1 | -452.57 Thousand EUR | 60.2% |
| 2023 Q4 | -332.77 Thousand EUR | 0.0% |
| 2023 Q3 | -332.77 Thousand EUR | 63.24% |
| 2023 FY | -1.57 Million EUR | 33.54% |
| 2022 Q1 | -590.62 Thousand EUR | -3.52% |
| 2022 Q3 | -567.18 Thousand EUR | 51.87% |
| 2022 Q4 | -1.13 Million EUR | -100.47% |
| 2022 FY | -2.36 Million EUR | -76.25% |
| 2022 Q2 | -1.17 Million EUR | -99.54% |
| 2021 Q1 | -385.14 Thousand EUR | -60.36% |
| 2021 Q3 | -285.28 Thousand EUR | 62.96% |
| 2021 Q2 | -770.28 Thousand EUR | -100.0% |
| 2021 FY | -1.34 Million EUR | -245.17% |
| 2021 Q4 | -570.56 Thousand EUR | -100.0% |
| 2020 Q4 | -240.17 Thousand EUR | -100.0% |
| 2020 Q3 | -120.08 Thousand EUR | 19.02% |
| 2020 Q2 | -148.29 Thousand EUR | -100.0% |
| 2020 FY | -388.46 Thousand EUR | -292.65% |
| 2020 Q1 | -74.14 Thousand EUR | 0.0% |
| 2019 FY | -98.93 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | 55.352% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 98.937% |
| Adocia SA | -21.16 Million EUR | 92.578% |
| Aelis Farma SA | -5.07 Million EUR | 69.068% |
| Biophytis S.A. | -17.02 Million EUR | 90.775% |
| Advicenne S.A. | -7.03 Million EUR | 77.66% |
| genOway Société anonyme | 1.56 Million EUR | 200.2% |
| IntegraGen SA | -171.39 Thousand EUR | -816.404% |
| Medesis Pharma S.A. | -3.95 Million EUR | 60.331% |
| Neovacs S.A. | -8.74 Million EUR | 82.036% |
| NFL Biosciences SA | -3.74 Million EUR | 58.064% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 2083.992% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | 50.466% |
| Sensorion SA | -22.06 Million EUR | 92.881% |
| Theranexus Société Anonyme | -6.82 Million EUR | 76.996% |
| TME Pharma N.V. | -6.73 Million EUR | 76.682% |
| Valbiotis SA | -7.36 Million EUR | 78.682% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 92.279% |
| argenx SE | -272.91 Million EUR | 99.424% |
| BioSenic S.A. | -28.77 Million EUR | 94.542% |
| Celyad Oncology SA | -8.44 Million EUR | 81.407% |
| DBV Technologies S.A. | -67.26 Million EUR | 97.665% |
| Galapagos NV | 211.69 Million EUR | 100.742% |
| Genfit S.A. | -28.89 Million EUR | 94.564% |
| GeNeuro SA | -14.75 Million EUR | 89.356% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 89.787% |
| Innate Pharma S.A. | -7.57 Million EUR | 79.251% |
| Inventiva S.A. | -110.42 Million EUR | 98.578% |
| MaaT Pharma SA | -19.71 Million EUR | 92.034% |
| MedinCell S.A. | -25.03 Million EUR | 93.727% |
| Nanobiotix S.A. | -39.7 Million EUR | 96.044% |
| Onward Medical N.V. | -36.18 Million EUR | 95.659% |
| Oryzon Genomics S.A. | -3.35 Million EUR | 53.154% |
| OSE Immunotherapeutics SA | -23 Million EUR | 93.172% |
| Oxurion NV | -18.96 Million EUR | 91.72% |
| Pharming Group N.V. | -9.75 Million EUR | 83.901% |
| Poxel S.A. | -35.09 Million EUR | 95.524% |
| GenSight Biologics S.A. | -26.22 Million EUR | 94.01% |
| Transgene SA | -22.32 Million EUR | 92.965% |
| Financière de Tubize SA | 88.15 Million EUR | 101.782% |
| UCB SA | 343 Million EUR | 100.458% |
| Valneva SE | -101.42 Million EUR | 98.451% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 94.458% |